Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
2013 · Calcified Tissue International · 57 citations
https://doi.org/10.1007/s00223-013-9734-6